NCT04598555

Brief Summary

The PRIME study is an observational, Real World Evidence study designed to collect the type of treatments that are currently prescribed to patients with mild asthma and to collect relevant clinical data that could reflect the control of the disease over a 6-month observational period according to the standard clinical practice.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
981

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2021

Geographic Reach
4 countries

59 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 12, 2020

Completed
10 days until next milestone

First Posted

Study publicly available on registry

October 22, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

February 25, 2021

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 2, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 2, 2022

Completed
Last Updated

September 27, 2022

Status Verified

September 1, 2022

Enrollment Period

1.5 years

First QC Date

October 12, 2020

Last Update Submit

September 26, 2022

Conditions

Outcome Measures

Primary Outcomes (4)

  • To describe the real-world patterns of treatment of subjects with mild asthma during a 6-month observational period.

    Frequency of asthma treatments for asthma management, regardless the duration: * by active substance * by drug class * distinguishing between "controller" and "reliever" treatments

    6-months period

  • To describe the real-world patterns of treatment of subjects with mild asthma during a 6-month observational period.

    Frequency of subjects experiencing asthma treatment switches, step-ups and step-downs during the observation period, along with the description of pattern of switch (in terms of sequence of treatments over time)

    6-months period

  • To describe the real-world patterns of treatment of subjects with mild asthma during a 6-month observational period.

    Frequency of treatment posology, stratified by type of asthma treatment

    6-months period

  • To describe the real-world patterns of treatment of subjects with mild asthma during a 6-month observational period.

    Duration of asthma treatments (in months): * overall * by drug class (i.e., any switch to drugs within the same class will be considered as a continuation of the treatment) and by active substance (i.e., any dose adaptation will be considered as a continuation of the same drug). This will be adapted according to data availability.

    6-months period

Secondary Outcomes (22)

  • To describe the Socio-demographics data of subjects with mild asthma at enrolment visit

    At enrolment

  • To describe the clinical characteristics of subjects with mild asthma at enrolment visit

    At enrolment

  • To describe the Daytime and night-time symptoms of subjects with mild asthma at enrolment visit

    At enrolment

  • To describe the Daytime and night-time symptoms of subjects with mild asthma at enrolment visit

    At enrolment

  • To describe the Asthma Diagnosis of subjects with mild asthma at enrolment visit

    At enrolment

  • +17 more secondary outcomes

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Mild asthma patients treated by step 1 or 2 treatments according to GINA report

You may qualify if:

  • Adult subject (aged ≥ 18 years) up to 75 years
  • Subject with confirmed asthma diagnosis
  • Subject in treatment for mild asthma with Step 1 or Step 2 according to GINA report
  • Subject with written privacy and study informed consent

You may not qualify if:

  • Subject enrolled in experimental (interventional) clinical trials, or receiving experimental treatments in the prior 3 months
  • Known pregnant or breast-feeding subject
  • Subject unable to understand and autonomously fill in questionnaires
  • Subject unable to use electronic devices to fill in e-diary, or without compatible electronic devices with access to the Internet
  • Subject who had asthma exacerbation(s) in the past 4 weeks prior to study entry
  • Subject with confirmed Chronic Obstructive Pulmonary Disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (59)

DE-008 Lungenarztpraxis Hellersdorf

Berlin, Germany

Location

DE-003 Praxis Pneumologie und Allergologie Dr. Ginko

Bonn, Germany

Location

DE-005 Praxis für Pneumologie und Innere Medizin

Fürstenwalde, Germany

Location

DE-006 Studieninstitut des Pneumologicums Halle

Halle, Germany

Location

DE-001 Salvus - Klinische Studien GmbH

Leipzig, Germany

Location

DE-007 POIS Leipzig GbR

Leipzig, Germany

Location

DE-004 Fortbildungs- und Studienzentrum Innere Medizin Marburg GbR

Marburg, Germany

Location

DE-009 Praxis Dr. Jansen

Menden, Germany

Location

DE-012 Pneumologisch-Internistische Gemeinschaftspraxis Elisenhof

Munich, Germany

Location

DE-010 Studienzentrum Dr. Schlenska

Peine, Germany

Location

DE-002 RespiRatio / Lungenpraxis Schleswig

Schleswig, Germany

Location

IT-028 Fisiopatologia Respiratoria Ospedale Ecclesiastico Miulli

Acquaviva delle Fonti, Italy

Location

IT-026 SOSD Allergologia A.O.U. Ospedali Riuniti

Ancona, Italy

Location

IT-005 UO Allergologia Ospedale S.Maria della Speranza

Battipaglia, 84091, Italy

Location

IT-019 UOC Pneumologia Ospedale Bellaria

Bologna, Italy

Location

IT-008 Pneumologia Policlinico Universitario Mater Domini

Catanzaro, Italy

Location

IT-006 SC MAR Univ A.O.U. Ospedali Riuniti Foggia

Foggia, Italy

Location

IT-001 UOC Pneumologia Fondazione Cà Granda Ospedale Maggiore Policlinico

Milan, Italy

Location

IT-007 Malattie Apparato Respiratorio A.O.U. Modena Policlinico

Modena, Italy

Location

IT-025 Allergologia e Immunologia clinica Policlinico Casula A.O.U. Cagliari

Monserrato, Italy

Location

IT-012 UOC Clinica Pneumologica A.O. dei Colli P.O. Monaldi

Napoli, Italy

Location

IT-016 SSD Intertiziopatie e Malattie del Polmone A.O.U. San Luigi Gonzaga

Orbassano, Italy

Location

IT-010 Medicina del Lavoro, Mal.Respiratorie e Tossicologia Azienda Ospedaliera

Perugia, Italy

Location

IT-013 UO Pneumologia A.O.U. Pisana P.O. Cisanello

Pisa, Italy

Location

IT-015 UOC Pneumologia Policlinico Univ. A. Gemelli

Roma, Italy

Location

IT-020 UOC Pneumologia A.O.U. Sant'Andrea

Roma, Italy

Location

IT-009 Pneumologia Clinica e Interventistica AOU Policlinico Universitario stabilim San Pietro

Sassari, Italy

Location

IT-021 Servizio Pneumologia PTA Ospedale Busacca

Scicli, Italy

Location

IT-024 Allergologia Casa della Salute

Scilla, Italy

Location

IT-029 Malattie Respiratorie e Trapianto Polmonare A.O.U. Senese Policlinico Le Scotte

Siena, Italy

Location

IT-017 Pneumologia Riabilitativa ICS Maugeri

Telese Terme, Italy

Location

IT-022 Pneumologia Univ. A.O.U. Città della Salute e della Scienza

Torino, Italy

Location

IT-003 UO Pneumologia Riabilitativa ICS Maugeri

Tradate, Italy

Location

IT-018 USD Allergologia AOUI Policlinico Rossi

Verona, Italy

Location

PL-012 Centrum Medyczne Pratia

Bydgoszcz, Poland

Location

PL-018 Prywatny Gabinet Ewa Gawrońska-Ukleja

Bydgoszcz, Poland

Location

PL-010 M2M Badania Kliniczne

Chorzów, Poland

Location

PL-015 Prywatny gabinet Pulmonologiczny at premises of Amicmed Medical Center

Grudziądz, Poland

Location

PL-005 Centrum Medyczne ALL-MED

Krakow, Poland

Location

PL-001 Poradnia Alergologii i Chorób Płuc, SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im Norberta Barlickiego

Lodz, Poland

Location

PL-013 SNZOZ Poradnia Specjalistyczna MedMed, Ul. Brzechwy 7a

Lodz, Poland

Location

PL-017 Gabinet Pulmonologiczny

Lodz, Poland

Location

PL-004 CDT Medicus

Lubin, Poland

Location

PL-009 Centrum Alergologii Sp. z o. o

Lublin, Poland

Location

Pl-006 Ppl Ps Magmed

Radom, Poland

Location

PL-014 Indywidualna Specjalistyczna Praktyka Lekarska Marzenna Tarnowska-Matusiak

Szczecin, Poland

Location

PL-016 NZOZ Poradnia Chorób Płuc i Alergologii

Słupsk, Poland

Location

PL-003 Praktyka lekarska Marzena Justyna Mierzejewska

Warsaw, Poland

Location

PL-011 Lekarze Specjaliści J.Małolepszy i Partnerzy

Wroclaw, Poland

Location

ES-005

Badalona, Spain

Location

ES-009 Hospital de la Santa Creu i Sant Pau

Barcelona, Spain

Location

ES-014 Hospital El Pilar

Barcelona, Spain

Location

ES-002 Hospital Universitario La Princesa

Madrid, Spain

Location

ES-004 'Hospital Universitario La Paz

Madrid, Spain

Location

ES-008 Fundación Jiménez Díaz

Madrid, Spain

Location

ES-010 Hospital Costa del Sol

Málaga, Spain

Location

ES-007 Complejo asistencial Universitario de Salamanca

Salamanca, Spain

Location

ES-11 Hospital Universitario Marqués de Valdecilla

Santander, Spain

Location

ES-003 Hospital Universitario Dr. Peset

Valencia, Spain

Location

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Eva Topole, Dr

    CHIESI Clinical Program Leader

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 12, 2020

First Posted

October 22, 2020

Study Start

February 25, 2021

Primary Completion

September 2, 2022

Study Completion

September 2, 2022

Last Updated

September 27, 2022

Record last verified: 2022-09

Data Sharing

IPD Sharing
Will not share

Locations